<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Nov. 8, 2018 (HealthDay News) — For premenopausal women with stage I to IIIA estrogen receptor-negative, progesterone receptor-negative breast cancer, goserelin plus chemotherapy is associated with an increased likelihood of becoming pregnant without an increased risk for adverse effects, according to a study published online Oct. 29 in the Journal of the National Cancer Institute<\/i>.<\/p>\n
Halle C.F. Moore, M.D., from the Cleveland Clinic Foundation, and colleagues examined long-term pregnancy and disease-related outcomes for patients in S0230\/POEMS, which enrolled premenopausal women with stage I to IIIA estrogen receptor-negative, progesterone receptor-negative breast cancer. Participants were randomly assigned to standard chemotherapy with or without goserelin. A total of 105 patients in the chemotherapy + goserelin arm and 113 in the chemotherapy arm were evaluable.<\/p>\n
The researchers found that at least one pregnancy was reported by more patients in the chemotherapy + goserelin arm versus the chemotherapy arm (five-year cumulative incidence, 23.1 versus 12.2 percent, respectively; odds ratio, 2.34; 95 percent confidence interval, 1.07 to 5.11; P = 0.03). There were non-statistically significant improvements in disease-free and overall survival with randomization to goserelin + chemotherapy (hazard ratios, 0.55 [95 percent confidence interval, 0.27 to 1.1; P = 0.09] and 0.45 [95 percent confidence interval, 0.19 to 1.04; P = 0.06], respectively).<\/p>\n
“Our final results show a means to improve quality of life for young women with hormone-receptor negative breast cancer,” Moore said in a statement. “If they want to be mothers, they can improve their chances safely and effectively.”<\/p>\n
Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca, which partially funded the study and provided the study drug.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n